{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:22:47Z","timestamp":1741839767992,"version":"3.38.0"},"reference-count":23,"publisher":"American Society of Consultant Pharmacists","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:p>Lupus treatment recently saw the approval of new drugs after a 12-year gap since the last approval of belimumab (Benlysta) in 2011. This article reviews these newly FDA-approved agents, which have demonstrated efficacy and safety in the management of systemic lupus erythematosus and\n lupus nephritis, a severe complication of the disease.<\/jats:p>","DOI":"10.4140\/tcp.n.2025.135","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T09:37:54Z","timestamp":1740735474000},"page":"135-144","source":"Crossref","is-referenced-by-count":0,"title":["A Review of Therapeutics for the Treatment of Lupus"],"prefix":"10.4140","volume":"40","author":[{"given":"Creaque C.","family":"Tyler","sequence":"first","affiliation":[{"name":"Texas Southern University Joan M. Lafleur College of Pharmacy and Health Sciences, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aireona C.","family":"Armagon","sequence":"additional","affiliation":[{"name":"Texas Southern University Joan M. Lafleur College of Pharmacy and Health Sciences, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildebrando E.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Texas Southern University Joan M. Lafleur College of Pharmacy and Health Sciences, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie","family":"Eaton","sequence":"additional","affiliation":[{"name":"Texas Southern University Joan M. Lafleur College of Pharmacy and Health Sciences, Houston, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum","volume":"76","year":"2020","journal-title":"Am J Kidney Dis."},{"year":"2024","key":"ref2","article-title":"National Resource Center on Lupus. Lupus Foundation of America."},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/11598550-000000000-00000","article-title":"Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment.","volume":"29","year":"2012","journal-title":"Drugs Aging."},{"issue":"1","key":"ref4","first-page":"1","article-title":"Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.","volume":"23","year":"2019","journal-title":"J Med Econ."},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"Clinical Practice Guideline for the management of Lupus Nephritis.","volume":"105","year":"2024","journal-title":"Kidney International"},{"year":"2024","key":"ref6","article-title":"Voclosporin. Lexi-Drugs. Lexicomp."},{"year":"2024","key":"ref7","article-title":"Voclosporin. Micromedex Solutions."},{"year":"2024","key":"ref8"},{"year":"2024","key":"ref9","article-title":"Belimumab. Micromedex Solutions."},{"year":"2024","key":"ref10","article-title":"Anifrolumab-fnia. Lexi-Drugs. Lexicomp."},{"year":"2024","key":"ref11","article-title":"Anifrolumab-fnia. Micromedex Solutions."},{"key":"ref12","first-page":"2024","article-title":"Anifrolumab-fnia (Saphnelo) Label. AstraZeneca. U.S. Food and Drug Administration.","volume":"15","year":"2021","journal-title":"Accessed August"},{"key":"ref13","first-page":"2024","article-title":"Belimumab (Benlysta) Label. GlaxoSmithKline. U.S. Food and Drug Administration.","volume":"15","year":"2012","journal-title":"Accessed August"},{"key":"ref14","first-page":"2024","article-title":"Voclosporin (Lupkynis) Label. Aurinia Pharmaceuticals Inc. U.S. Food and Drug Administration.","volume":"15","year":"2021","journal-title":"Accessed August"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/2040622310380100","article-title":"Contemporary treatment of systemic lupus erythematosus: an update for clinicians.","volume":"1","year":"2010","journal-title":"Ther Adv Chronic Dis."},{"key":"ref16","first-page":"2022","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.","volume":"14","year":"2022","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"17","key":"ref17","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2169\/internalmedicine.4317-19","article-title":"Efficacy and safety of hydroxychloroquine therapy for systemic lupus erythematosus patients depend on administration dose.","volume":"59","year":"2020","journal-title":"Int Med."},{"key":"ref18","first-page":"2024","article-title":"Cyclosporine (Neoral). Package insert. Novartis Pharmaceuticals Inc. U. S. Food and Drug Administration.","volume":"15","year":"2009","journal-title":"Accessed August"},{"key":"ref19","first-page":"2024","article-title":"Rituxan (Rituximab) Label. Biogen Idec Inc. and Genentech USA, Inc. U.S. Food and Drug Administration.","volume":"15","year":"2020","journal-title":"Accessed August"},{"key":"ref20","first-page":"2023","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis.","volume":"22","year":"2020","journal-title":"N Engl J Med."},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus.","volume":"382","year":"2020","journal-title":"N Engl J Med."},{"issue":"10289","key":"ref22","first-page":"2070","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [published correction appears in Lancet.] 2021;397(10289):2048].","volume":"397","year":"2021","journal-title":"Lancet."},{"issue":"4","key":"ref23","first-page":"383","article-title":"Systemic lupus erythematosus: diagnosis and treatment.","volume":"107","year":"2023","journal-title":"Am Fam Physician."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2025\/00000040\/00000003\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T20:15:09Z","timestamp":1741810509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2025.135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["2639-9636(20250301)40:3L.135;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2025.135","relation":{},"ISSN":["2639-9636"],"issn-type":[{"type":"print","value":"2639-9636"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}